Radioconjugation of internalizing antibodies

Details Radioconjugation of internalizing antibodies Radioconjugation of internalizing antibodies

2006-02-14

2006-02-14

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

C424S179100, C514S005200, C530S300000, C530S391500

Reexamination Certificate

active

06998106

ABSTRACT:
Antibodies to cell surface ligands such as EGFRvIII can be used to therapeutically or diagnostically deliver a radiolabel to tumor cells with high selectivity. The utility of radioconjugated internalizing antibodies is limited, however, by release of the label and its reuptake into normal cells. The invention provides new technology for radioconjugation of internalizing antibodies which reduces the release of label and improves retention of radioconjugated antibodies in lysosomes, where radiation is more effectively and selectively delivered to the nucleus of tumor cells.

REFERENCES:
patent: 4614723 (1986-09-01), Schmidt et al.
patent: 4885153 (1989-12-01), Wilbur et al.
patent: 5130116 (1992-07-01), Woo et al.
patent: 5302700 (1994-04-01), Zalutsky et al.
patent: 5541297 (1996-07-01), Hansen et al.
patent: WO 90/09162 (1990-08-01), None
patent: WO 98/08548 (1998-03-01), None
patent: WO 99/11294 (1999-03-01), None
Emery et al , “Strategies for Humanizing Antibodies” in Antibody Engineering, 2nd Edition, Carl A. Borrebaeck, Ed., pp. 159-183, 1995.
Kindzelskii et al, “Imaging the Spatial Distribution of Membrane Receptors during Neutrophil Phagocytosis.” Journal of Structural Biology, vol. 113, pp. 191-198, 1994.
Miller et al, “Proteolytic Studies of Homologous Peptides and N-Substituted Gylcine Peptoid Oligomers.” Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 22, pp 2657-2662, 1994.
Mathews and Van Holde, Biochemistry (textbook), 2nd edition, pp. 165-171.
Bowie et al, “Deciphering the Message in Protein Sequences . . . ” Science, vol. 247, pp. 1306-1310.
Derwent Accession No. 1994-026637, Barnett et al, CA 2094658A, Oct. 24, 1993. (abstract).
Abstract of Reist et al (Cancer research, 1995, vol. 55, pp. 4375-4382).
Abstract of Wikstrand et al (Cancer Research, Sep. 1997, vol. 57, pp. 4130-4140).
Schlom (In: Molecular Foundations of Oncology, 1991, pp. 95-134).
Michael R. Zalutsky, “Astatine and Iodine Radiolabeled Monoclonal Antibodies” CRISPAbstract to NIH Grant 5R01CA42324-12 (published Jun. 24, 1994) <http://commons.cit.nih.gov/crisp—historical/owa/crisp—lib.getdoc?textkey=2330729&p—grant—num=5R01CA42324-12&p—query=&ticket=130238&p—audit—session—id=57936&p—keywords=>.
“Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxings and Drugs Immunomedics Invents New Targeted Therapies for Cancers and Infectious Diseases” PR Newswire via Individual, Inc., Aug. 14, 1996.
C.J. Reist et al. “Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate” Cancer Res. 1996 No. 1;56(21 :4970-7 Nov. 1, 1996.
C.J. Reist et al. “In Vitro and In Vivo Behavior of Radiolabeled Chimeric Anti-EGFRvIII Monoclonal Antibody: Comparison with its Murine Patent” Nuclear Medicine & Biology, vol. 24, pp. 639-647 1997.
S.R. Govindan et al. “A non-metabolizable TPA-peptide (DPEP) approach for production of a residualizing Iodine radiolabeled for targeting human lung cancer xenografts” Proceedings of the American Association for Cancer Research, vol. 39, Mar. 1996 #2585 (Abstract).
S.V. Govindan et al. “Peptide-based Residualizing Radioiodine Labels for Radioimmunotherapy” Journal of Nuclear Medicine, vol. 39, No. 5, May 1998 No. 989 (Abstract).
C.J. Reist et al. “Improved Targeting of an Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody in Tumor Xenografts after Labeling Using N-Succinimidyl 5-Iodo-3-Pyridinecarboxylate” Cancer Research 57, 1510-1515 Apr. 15, 1997.
S.V. Govindan, et al., “Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radionated Peptides Containing D-Amino Acids”, Bioconjugate Chemistry, 1999 Mar.-Apr. 10 (2) 231-240.
M. R. Zalutsky, et al., “RadioiodinationVia D-Amino Acid Peptide Enhances Tumor Targeting of an Internalizing Anti-EGFRvIII Monoclonal Antibody”, Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2000, No. 41, pp. 706.
Y. Arano, et al., “Conventional and High Yield Synthesis of DTPA-Conjugated Peptides: Application of a Monoreactive DTPA to DTPA-D-Phe-Octreotide Synthesis”, Bioconjugate Chemistry, vol. 8, 1997, pp. 442-446.
T. M. Behr, et al., “Reduction of the Renal Uptake of Radiolabeled Monoclonal Antibody Fragments by Cationic Amino Acids and Their Derivatives”, Cancer Research, US, American Association for Cancer Research, Baltimore, MD, vol. 55, Sep. 1, 1995, pp. 3825-3834.
K. Zimmermann, et al., “A Triglycine Linker Improves Tumor Uptake and Biodistributions of 67-Cu-Labeled Anti-Neuroblastoma MAbchCE7 F(ab′)2 Fragments—Reactivity Studies of the Pendant Carboxylic Group in a Macrocyclic Cu2+ Complex Towards Amide Formation and its Use as a Protein Labeling Agent”, Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, vol. 26, No. 8, Nov. 1999, pp. 943-950.
C. F. Foulon, et al., “Radioiodination Via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody”, Cancer Research, vol. 60, Aug. 15, 2000, pp. 4453-4460.
M. R. Zalutsky, et al., “Astatine-211-Labeled Radiotherapeutics: an Emerging Approach to Targeted Alpha Particle Radiotherapy”, Current Pharmaceutical Design, vol. 6 Sep. 2000, pp. 1433-1455.
C. J. Reist, et al., “In Vitro and In Vivo Behavior of Radiolabeled Chimeric Anti-EGFRvIII Monoclonal Antibody: Comparison with its Murine Parent”, Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, vol. 24, No. 7, Oct. 1, 1997, pp. 639-647.
C. J. Reist, et al., “Astatine-211-Labeling of Internalizing Anti-RGFRvIII Monoclonal Antibody Using N-Succinimidyl 5-′At!astato-3-Pyridinecarboxylate—Preservation of Immunoreactivity and in Vivo Localizing Capacity”, Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, vol. 26, No. 4, May 1999, pp. 405-411.
J. Sundin, et al., “High Yield Direct Br-Bromination of Monoclonal Antibodies Using Chloramine-T—Detection of Colorectal Carcinoma with Positron-Emitting Copper-64-Labeled Monoclonal Antibody”, Nuclear Medicine and Biology, US, Elsevier Science Publishers, New York, NY, vol. 26, No. 8, Nov. 1999, pp. 923-929.
R. Stein, et al., “Targeting Human Cancer Xenografts with Monoclonal Antibodies Labeled Using Radioiodinated Diethylenetriaminepentaacetic Acid-Appended Peptides”, Clinical Cancer Research, vol. 5, No. Suppl., Oct. 1999, pp. 3079s-3087s.

Affiliated with

Also associated with

Rating

Radioconjugation of internalizing antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radioconjugation of internalizing antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioconjugation of internalizing antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3631665